Loading…
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 10,940 other HR bills in the 119th — cohort avg 30d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (5)
2026 · third_quarter · Health Issues
Referred to the House Committee on Energy and Commerce.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Preeclampsia Risk Evaluation and Evidence-based Management through Personalized Testing Act PREEMPT Act (H.R. 9061) to promote the appropriate use of advanced preeclampsia biomarker testing as part of the Medicaid program. Seeking Senate companion legislation.
Client expense: Not reported · Firm income: $21,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Health Issues
General discussions related to clinical trials infrastructure and government labs, and related matters. General discussions regarding diagnostic reimbursement policies. General discussions regarding domestic pharmaceutical manufacturing. H.R. 5269/S. 2761: Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act of 2025 - all provisions of the bill. H.R. 5343/S. 1717: Ensuring Patient Access to Critical Breakthrough Products Act - all provisions of the bill. H.R. 9061: Preeclampsia Risk Evaluation and Evidence-based Management through Personalized Testing (PREEMPT) Act - all provisions of the bill.
Client expense: $550,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE, White House Office
2026 · second_quarter · Health Issues
Abortion access (general); Access to mifepristone (general); Contraception (general); Maternal mortality and morbidity (general); H.R. 8651/S. _____, Advancing Safe Medications for Moms and Babies Act; Obstetric and gynecologic care in rural and underserved areas (general); impact of closures of labor and delivery units in rural hospitals on patient access to care and maternal morbidity and mortality; abortion training in obstetrics and gynecology residency programs (general); Teaching Health Center Graduate Medication Education program (general); implementation of P.L. 119-21, One Big, Beautiful Bill Act; implementation of Sec. 6501 of P.L. 119-75, Preventing Maternal Deaths Reauthorization Act; Telemedicine (general); S. 380/H.R. 1254, Rural Obstetrics Readiness Act; S. 1834/H.R. 3762, Supporting Healthy Moms and Babies Act; H.R. 7973, Momnibus Act; H.R. 7830, WELLS Act; H.R.8159, Gynecologic Pain Management Study Act; H.R.8160, Premenstrual Dysphoric Disorder Awareness and Research Act; H.R. 9441, SAFE Training for OBGYNs Act; H.R. 9061, PREEMPT Act; H.Res. 1282, a resolution recognizing ACOGs 75th anniversary; H.R. 8358, Breast Cancer Research Stamp Reauthorization Act; S. Res. 710, a resolution recognizing Maternal Mental Health Day; H.R. 9090/S. 4503, Advancing Menopause Care and Mid-Life Womens Health Act; H.Res. 1323, a resolution recognizing National Menstrual Health Awareness Month; H.R. 8500, Timely Access to Coverage Decisions Act; H.R. 7694, Gwenns Law; S. 4878, Reproductive Health Care Training Act; H.R. _____/S. _____, Right to IVF Act; S. 4494, America Cures Act; maternal mortality review committees (general); Patient-physician relationship (general); Obstetrician-gynecologist workforce (general); Substance use disorder during pregnancy (general); Maternal mental health (general); Insurance coverage for infertility (general); Protections for in vitro fertilization (general); Vaccination (general); childhood vaccine recommendations (general); Task Force on Research Specific to Pregnant Women and Lactating Women (PRGLAC) recommendations (general); inclusion of pregnant and lactating women in clinical trials (general); pregnancy exposure registries (general); NIH/NICHD womens health research (general); access to fertility services and treatments (general); Restorative Reproductive Medicine (general); Advisory Committee on Immunization Practices (ACIP); COVID vaccine during pregnancy (general); S. 4550/H.R. 8807, Maternal Health Pandemic Response Act; United States Preventive Services Taskforce (general); hormone therapy for menopause symptoms (general); acetaminophen use during pregnancy (general); SSRI use during pregnancy (general); Pregnancy Risk Assessment Monitoring System (PRAMS); Maternal Mortality Review Information Application (MMRIA); FACE Act implementation; Nexplanon REMS; chaperones during sensitive procedures (general); FDA regulation of flavored e-cigarettes (general); ORR policies regarding pregnant minors (general); breast cancer risk assessment (general).
Client expense: $96,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Health Issues
Maternal and infant health legislation: SHINE for Autumn Act (H.R. 5469, S.2858), NIH IMPROVE Act (H.R. 6238, S.3254), Healthy Start Reauthorization Act (H.R.3302, S.3799), Momnibus Act (H.R. 7973), Dads Matter Act (H.R. 5828, S. 2131), Rural Obstetrics Readiness Act (H.R. 1254, S. 380), and PREEMPT Act (H.R. 9061), legislation focused on coverage guidance on tests for the screening and early detection of preeclampsia.
Client expense: $60,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Health Issues
Healthcare issues related to clinical laboratories; H.R. 5269/S. 2761,the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, provisions relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; H.R. 5582/S. 2355, the Patients Deserve Price Tags Act, and H.R. 9393, the Lower Costs, More Transparency Act, provisions relating to lab test price transparency; H.R. 8500, the Timely Access to Coverage Decisions Act, provisions relating to establishment of standards for Medicare local coverage decisions; H.R. 8890, the Enhancing Clinical Laboratory Innovation and Access (Enhancing CLIA) Act, provisions relating to oversight of laboratory-developed tests; H.R. 9061, the Preeclampsia Risk Evaluation and Evidence-based Management through Personalized Testing (PREEMPT) Act, provisions relating to Medicaid coverage of preeclampsia screening tests; H.R. 8413, the Securing and Establishing Consumer Uniform Rights and Enforcement over Data (SECURE Data) Act, provisions relating to privacy of health care data; A draft of the AI Workforce Assessment and Research (AWARE) Act, provisions relating to disclosure of information on the use and impact of artificial intelligence in employment matters; A draft of the Great American AI Act, provisions relating to regulation of artificial intelligence; Federal policy relating to oversight of laboratory benefit managers; Federal policy relating to access to mandatory code sets for administrative transactions; and Federal policy relating to supply chain issues affecting pre-clinical biomedical research for drug development.
Client expense: $270,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Health Issues
General discussions related to clinical trials infrastructure and government labs, and related matters. General discussions regarding diagnostic reimbursement policies. General discussions regarding domestic pharmaceutical manufacturing. H.R. 5269/S. 2761: Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act of 2025 - all provisions of the bill. H.R. 5343/S. 1717: Ensuring Patient Access to Critical Breakthrough Products Act - all provisions of the bill. H.R. 9061: Preeclampsia Risk Evaluation and Evidence-based Management through Personalized Testing (PREEMPT) Act - all provisions of the bill.
Client expense: $280,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Veterans Affairs, Dept of (VA), White House Office
2026 · second_quarter · Health Issues
Preeclampsia Risk Evaluation and Evidence-based Management through Personalized Testing Act PREEMPT Act (H.R. 9061) to promote the appropriate use of advanced preeclampsia biomarker testing as part of the Medicaid program. Seeking Senate companion legislation.
Client expense: Not reported · Firm income: $21,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
| Republican |
| CA |
| Yvette D. Clarke | Democratic | NY |